CareDx, Inc. is a molecular diagnostics company that discovers, develops, and commercializes diagnostic solutions for transplant patients worldwide. The company offers AlloMap, a non-invasive blood test used to aid in the identification of heart transplant recipients with stable graft function who have a low probability of moderate to severe acute cellular rejection. It also provides AlloSure, a donor-derived cell-free DNA test used to identify kidney transplant recipients with active rejection and surveillance allograft health; and HeartCare, a non-invasive solution to monitor the presence of antibodies in the blood stream that can lead to heart transplant rejection. CareDx, Inc. was founded in 1998 and is headquartered in Brisbane, California.